Several MD Anderson-led studies at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting focus on using immunotherapy to provide new treatment options for rare, aggressive cancers, including anaplastic thyroid cancer (ATC), glioblastoma, leptomeningeal disease (LMD) and soft-tissue sarcomas. For most of these rare diseases, survival is poor and few – if any – effective treatment options are currently available.
As...
Brian Odle has now overcome four cancer diagnoses in his life, thanks to inheriting a mutation in the TP53 gene. This inherited condition...
Julia Pitts tried all the standard treatment options with her local physicians after she was diagnosed with metastatic uterine cancer in 2015...
Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer types. Breast cancers related to a BRCA mutation are also more likely to be triple-negative breast cancer (TNBC), which can be more aggressive and difficult to treat.
Previous studies have shown that targeted drug therapies may be more effective in treating BRCA-associated breast cancers than...
Strategies to procure high-quality core-needle biopsy (CNB) specimens are critical for making basic tissue diagnoses and for ancillary testing...
In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall survival...
A deep sequencing study of brain metastases from MD Anderson revealed many similarities but also distinct differences relative to the primary...
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in cancer,...
A Phase I chemoprevention clinical trial led by MD Anderson researchers found that naproxen, an over-the-counter anti-inflammatory drug, is...
Results from a clinical trial led by MD Anderson researchers showed that combining the immunotherapy checkpoint inhibitor drug durvalumab...